Reported Earlier, FDA Approves Medtronic's PulseSelect Pulsed Field Ablation System For The Treatment Of Both Paroxysmal And Persistent Atrial Fibrillation
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Medtronic's PulseSelect Pulsed Field Ablation System for treating paroxysmal and persistent atrial fibrillation. This marks the first PFA technology to receive FDA approval, following its recent CE Mark in Europe in November.
December 14, 2023 | 6:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's PulseSelect Pulsed Field Ablation System has been approved by the FDA for atrial fibrillation treatment, which could enhance the company's product portfolio and market position in cardiac therapies.
The FDA approval of Medtronic's PulseSelect PFA System is a significant milestone for the company, likely to result in increased investor confidence and potential market share growth in the cardiac therapy sector. As the first PFA technology approved by the FDA, it positions Medtronic at the forefront of this medical field, which could translate into increased sales and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100